Targeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting chimeras) has evolved into a broader “induced proximity” field that now includes molecular glue degraders, degrader-antibody conjugates (DACs), lysosome-targeting chimeras (LYTACs), RNA degraders and other proximity-based therapeutics.
Targeted Protein Degradation: Designed to destroy
Background, Latest NewsTargeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting chimeras) has evolved into a broader “induced proximity” field that now includes molecular glue degraders, degrader-antibody conjugates (DACs), lysosome-targeting chimeras (LYTACs), RNA degraders and other proximity-based therapeutics.
PharmNovo raises €3.5M for phase 2 pain trial
Latest NewsSwedish biotech PharmNovo has raised about SEK39m (€3.5m) to help finance a phase 2 study of PN6047, its experimental treatment for neuropathic pain.
AB Science cuts three trials in pipeline reset
Latest NewsFrench biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leukaemia.
Roche drops two Huntington’s programmes from Ionis
Latest NewsRoche has discontinued two Huntington’s disease programmes after its Ionis-partnered drug tominersen failed to improve patients’ symptoms and a separate candidate raised concerns in animal studies.
AstraZeneca and Ionis miss in key ATTR-CM trial
Latest NewsAstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), denting hopes that the RNA-targeted therapy could compete in one of cardiology’s fastest-growing rare disease markets.
GSK ends Alector neuroscience deal after trial failures
Latest NewsGSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks.
Alchemab extends Series A with £25m from British Business Bank
Latest NewsCambridge-based Alchemab Therapeutics has added £25m (€29m) to its Series A financing, taking the round to £109m (€128m) and giving the UK biotech fresh capital to advance its AI-enabled antibody pipeline.
AZ buys ex-China rights to Sino’s COPD drug for $2.1bn
Latest NewsAstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona Pharma acquisition.
Boehringer licenses PVT virus platform for cancer vaccines
Latest NewsBoehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines.
Graph Therapeutics raises $5m to advance I&I pipeline
Latest NewsAustria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on its AI-enabled platform.